Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million from investors. Its total funding is more than $200 million. Cardiac ...
KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions ®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an ...
Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System® New data highlight ...
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System® KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions®, a leader ...
New data highlight multi-center 5-year durability, 10-year survival, and the largest single-center experience across both HFrEF and HFpEF patients with functional mitral regurgitation KIRKLAND, Wash., ...
Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever ...
New data highlight multi-center 5-year durability, 10-year survival, and the largest single-center experience across both HFrEF and HFpEF patients with functional mitral regurgitation Cardiac ...
The Carillon Mitral Contour System is the only commercially available indirect mitral annuloplasty device, designed to treat a broad and expanding population of patients living with functional mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results